Ogawa Kazuma
Institute for Frontier Science Initiative, Kanazawa University.
Graduate School of Medical Sciences, Kanazawa University.
Chem Pharm Bull (Tokyo). 2019;67(9):897-903. doi: 10.1248/cpb.c19-00274.
The word "theranostics," a portmanteau word made by combining "therapeutics" and "diagnostics," refers to a personalized medicine concept. Recently, the word, "radiotheranostics," has also been used in nuclear medicine as a term that refer to the use of radioisotopes for combined imaging and therapy. For radiotheranostics, a diagnostic probe and a corresponding therapeutic probe can be prepared by introducing diagnostic and therapeutic radioisotopes into the same precursor. These diagnostic and therapeutic probes can be designed to show equivalent pharmacokinetics, which is important for radiotheranostics. As imaging can predict the absorbed radiation dose and thus the therapeutic and side effects, radiotheranostics can help achieve the goal of personalized medicine. In this review, I discuss the use of radiolabeled probes targeting bone metastases, sigma-1 receptor, and αβ integrin for radiotheranostics.
“治疗诊断学”一词是由“治疗学”和“诊断学”组合而成的混成词，指的是个性化医疗概念。最近，“放射治疗诊断学”这个词也在核医学中被用作一个术语，指使用放射性同位素进行联合成像和治疗。对于放射治疗诊断学而言，可以通过将诊断性和治疗性放射性同位素引入同一前体来制备诊断探针和相应的治疗探针。这些诊断和治疗探针可以设计成具有等效的药代动力学，这对放射治疗诊断学很重要。由于成像可以预测吸收的辐射剂量，进而预测治疗效果和副作用，放射治疗诊断学有助于实现个性化医疗的目标。在这篇综述中，我讨论了用于放射治疗诊断学的靶向骨转移、σ-1受体和αβ整合素的放射性标记探针的应用。
